Sex: F
Vaccine: COVID19, COVID19
Symptoms: Atelectasis, Chest X-ray abnormal, Chest discomfort, Electrocardiogram abnormal, Fear
Clinical narrative: Her pulse was 146 and 45 minutes later, her pulse was 136/her pulse was 105/6 hours later her pulse continued to come down; Her pulse was 146 and 45 minutes later, her pulse was 136/her pulse was 105/6 hours later her pulse continued to come down; Throwing PVCs like crazy; Hard to take a deep breathe; This is a spontaneous report from a contactable Nurse (patient). A (Age: 64, Unit: Unknown) female patient received BNT162B2 first dose on 14Jan2021 at single dose for covid-19 immunization. Medical history included thyroidectomy and concomitant medications were not reported. Patient wanted to know if tachycardia had been reported as an adverse reaction following administration of the Covid vaccine 12 hours later. Caller stated that she received her first dose of the Covid vaccine last Thursday (14Jan2021). Twelve and a half hours after administration of the vaccine (14Jan2021), her pulse was 146 and 45 minutes later, her pulse was 136. Caller's husband took her to the ER and in the 5.5 hours she was there, she received IV saline and had been "throwing PVCs like crazy." She was released from the ER around 3 a.m 15Jan2021., in which her pulse was 105 and she was throwing PVCs periodically at this time. 6 hours later her pulse continued to come down. Caller stated that it is still hard to take a deep breathe, but her oxygen saturations have been fine, ranging in the 70s to 105, then back down to 80s. Caller stated that she has no comorbidities and has only had a thyroidectomy in which her TSH is normal on 14Jan2021. She has no cardiac problems, in which a cardiologist did an EKG and found it to be normal on 14Jan2021. The cardiologist advises her to "absolutely take the second dose." Caller stated that she is scheduled for a stress test and echo on the 28Jan2021. Caller is also scheduled to receive the second dose on 04Feb2021. The outcome of the events was unknown.  Information on the Batch/Lot number has been requested.; Sender's Comments: Based on available information, a possible contributory role of the subject product, BNT162B2 vaccine, cannot be excluded for the reported events of tachycardia, premature ventricular contractions and abnormal pulse  due to temporal relationship. There is limited information provided in this report.  Additional information is needed to better assess the case, including complete medical history, diagnostics including EKG at baseline and during subject drug therapy, echocardiogram, cardiac enzymes, electrolytes, chemistry panel and serum toxicology screen, counteractive treatment measures and concomitant medications.  This case will be reassessed once additional information is available.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.